American College of Cardiology Urges Heart Attack, Stroke Patients to Seek Medical Help

Through its CardioSmart patient initiative, the American College of Cardiology has issued guidance to encourage patients experiencing a heart attack or stroke to call 911.  While hospitals across the United States are experiencing an influx of COVID-19 patients, clinicians are reportedly seeing fewer patients going to emergency rooms for heart attack or stroke. Experts worry that patients who need critical care are delaying their treatment over concerns about the novel coronavirus.

“Due to fears of contracting COVID-19 or taking up space in hospitals, patients experiencing a heart attack or stroke are delaying their essential care, causing a new public health crisis,” said Martha Gulati, MD, FACC, editor-in-chief of CardioSmart.org. “Hospitals and catheterization labs are still treating heart attack and stroke, not just COVID-19, and are taking the utmost precautions to ensure that the novel coronavirus not be spread. The faster a patient is treated, the higher the outcome of survival and lower the risk for complications. No patient should delay their care.”

A new CardioSmart infographic, “Coronavirus and Your Heart: Don’t Ignore Heart Symptoms,” encourages patients to pay close attention to heart attack or stroke symptoms, particularly if they have a pre-existing heart condition, and call 911 immediately if they believe they’re having a heart attack or stroke. The infographic details common heart attack and stroke symptoms and ensures hospitals are taking steps to protect them from COVID-19. The infographic also encourages patients to continue routine heart care to ensure they stay healthy, which may be accomplished through telehealth (remote or virtual visit) or a phone call with their clinician.

“We encourage clinicians to widely distribute these tools to their patients. Make sure that patients know when telehealth is an appropriate option, and when they should call 911 instead,” Gulati said. “Clinicians should work with patients to ensure medication adherence, and always continue to advocate for heart-healthy measures that can be taken even in times of self-isolation and social distancing.”

CardioSmart serves as the ACC’s patient engagement initiative. Reviewed by experts in the CardioSmart COVID-19 Response Work Group, the new infographic joins the full collection of ACC COVID-19 resources, including clinical bulletins, journal articles, patient summaries and more. For more information about how COVID-19 affects patients with pre-existing heart conditions, and to download the full infographic, visit the CardioSmart COVID-19 Hub.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy